Browse everything: Tickers A–Z · Issuers · Comparisons · Tags
BDRX Stock — Biodexa Pharmaceticals
Biodexa Pharmaceticals (BDRX)
Updated October 16, 2026.
BDRX is a Stock. Total return is -100.0% over the past 10.9 years, 438.2 points behind SPY at 338.2%.
Biodexa Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapies for Type 1 diabetes, various cancers, and familial adenomatous polyposis, along with proprietary drug delivery platforms. The company does not currently distribute dividends and operates as an early-stage development business typical of the biopharma sector. This security appeals to investors seeking exposure to clinical-stage pharmaceutical innovation rather than current income.
BDRX dividend yield and income
Price as of 2026-10-16.
The payment date is 03/03/2020.
BDRX performance versus SPY
Price and return data through 2026-10-16.
Total return is -100.0% over the past 10.9 years, 438.2 points behind SPY at 338.2%. Over the past year its total return — price change plus distributions reinvested — is -98.9%. Its deepest 1-year drawdown was 99.2%.
| Window | Total return | CAGR |
|---|---|---|
| 1M | -52.5% | — |
| 3M | -78.6% | — |
| 6M | -86.9% | — |
| YTD | -96.0% | — |
| 1Y | -98.9% | — |
| 2Y CAGR | — | -96.70% |
| 3Y CAGR | — | -95.70% |
| 5Y CAGR | — | -94.60% |
| 10Y CAGR | — | -76.80% |
| Since inception (10.9 years) | -100.0% | -73.90% |
BDRX key facts
- Asset type
- Stock
- Asset class
- Equity
- Inception date
- 12/07/2015
- Distribution frequency
- None
- Last close
- $0.46 (as of 2026-10-16)
- Market cap
- $1,005,352
- Average volume
- 608347.0
- Payment date
- 03/03/2020
- Beta
- 1.283
- Payout ratio
- 0.0%
- P/E ratio
- 0.01
- EPS
- $63.74
How Dividend Vision calculates yield and returns
Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.
Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology
Sources and review
Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.
Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.
BDRX risks and drawbacks
Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 99.2%.
Who may consider BDRX — and who may not
It is a weaker fit for investors who need monthly cash flow (BDRX does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.
More on BDRX
Frequently asked questions
Does BDRX pay monthly?
No. BDRX does not currently distribute.
When does BDRX pay a dividend?
BDRX does not currently distribute. The payment date is 03/03/2020.
How has BDRX performed?
Total return is -100.0% over the past 10.9 years, 438.2 points behind SPY at 338.2%. Over the past year its total return — price change plus distributions reinvested — is -98.9%. Its deepest 1-year drawdown was 99.2%.
Tickers
Holdings as-of date unavailable.
| Ticker | Name | Weight |
|---|
See how this investment would fit into your portfolio.